Halloran CM - Search Results

1

hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA.

Aughton K, Elander NO, Evans A, Jackson R, Campbell F, Costello E, Halloran CM, Mackey JR, Scarfe AG, Valle JW, Carter R, Cunningham D, Tebbutt NC, Goldstein D, Shannon J, Glimelius B, Hackert T, Charnley RM, Anthoney A, Lerch MM, Mayerle J, Palmer DH, Büchler MW, Ghaneh P, Neoptolemos JP, Greenhalf W. Aughton K, et al. Among authors: halloran cm. Cancers (Basel). 2021 Nov 17;13(22):5758. doi: 10.3390/cancers13225758. Cancers (Basel). 2021. PMID: 34830914 Free PMC article.

2

PANC Study (Pancreatitis: A National Cohort Study): national cohort study examining the first 30 days from presentation of acute pancreatitis in the UK.

PANC Study Collaborative. PANC Study Collaborative. BJS Open. 2023 May 5;7(3):zrad008. doi: 10.1093/bjsopen/zrad008. BJS Open. 2023. PMID: 37161673 Free PMC article.

3

Gene therapy for pancreatic cancer--current and prospective strategies.

Halloran CM, Ghaneh P, Neoptolemos JP, Costello E. Halloran CM, et al. Surg Oncol. 2000 Dec;9(4):181-91. doi: 10.1016/s0960-7404(01)00011-1. Surg Oncol. 2000. PMID: 11476989 Review.

4

Complications of pancreatic cancer resection.

Halloran CM, Ghaneh P, Bosonnet L, Hartley MN, Sutton R, Neoptolemos JP. Halloran CM, et al. Dig Surg. 2002;19(2):138-46. doi: 10.1159/000052029. Dig Surg. 2002. PMID: 11979003 Free article. Review.

5

5-Fluorouracil or gemcitabine combined with adenoviral-mediated reintroduction of p16INK4A greatly enhanced cytotoxicity in Panc-1 pancreatic adenocarcinoma cells.

Halloran CM, Ghaneh P, Shore S, Greenhalf W, Zumstein L, Wilson D, Neoptolemos JP, Costello E. Halloran CM, et al. J Gene Med. 2004 May;6(5):514-25. doi: 10.1002/jgm.540. J Gene Med. 2004. PMID: 15133762

6

Current standards of surgery for pancreatic cancer.

Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP. Alexakis N, et al. Br J Surg. 2004 Nov;91(11):1410-27. doi: 10.1002/bjs.4794. Br J Surg. 2004. PMID: 15499648 Review.

7

Trials of gene therapy for pancreatic carcinoma.

Halloran CM, Ghaneh P, Costello E, Neoptolemos JP. Halloran CM, et al. Curr Gastroenterol Rep. 2005 Jun;7(3):165-9. doi: 10.1007/s11894-005-0028-7. Curr Gastroenterol Rep. 2005. PMID: 15913472 Review. No abstract available.

8

Carbohydrate antigen 19.9 accurately selects patients for laparoscopic assessment to determine resectability of pancreatic malignancy.

Halloran CM, Ghaneh P, Connor S, Sutton R, Neoptolemos JP, Raraty MG. Halloran CM, et al. Br J Surg. 2008 Apr;95(4):453-9. doi: 10.1002/bjs.6043. Br J Surg. 2008. PMID: 18161888

9

Minimal access retroperitoneal pancreatic necrosectomy: improvement in morbidity and mortality with a less invasive approach.

Raraty MG, Halloran CM, Dodd S, Ghaneh P, Connor S, Evans J, Sutton R, Neoptolemos JP. Raraty MG, et al. Among authors: halloran cm. Ann Surg. 2010 May;251(5):787-93. doi: 10.1097/SLA.0b013e3181d96c53. Ann Surg. 2010. PMID: 20395850

10

Surgical oncology: PBD-better stents in specialized centers are needed.

Neoptolemos JP, Halloran CM. Neoptolemos JP, et al. Among authors: halloran cm. Nat Rev Clin Oncol. 2010 May;7(5):244-6. doi: 10.1038/nrclinonc.2010.45. Nat Rev Clin Oncol. 2010. PMID: 20428218 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

91 results

Search Page